- Report
- March 2026
- 150 Pages
Global
From €5431EUR$5,950USD£4,654GBP
- Report
- September 2026
- 185 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- September 2026
- 483 Pages
Global
From €5339EUR$5,850USD£4,575GBP
- Report
- May 2026
- 363 Pages
Global
From €4098EUR$4,490USD£3,512GBP
- Report
- February 2026
- 250 Pages
Global
From €4098EUR$4,490USD£3,512GBP
- Report
- October 2025
- 160 Pages
Global
From €2884EUR$3,160USD£2,471GBP
€3605EUR$3,950USD£3,089GBP
- Report
- July 2026
- 218 Pages
Global
From €4380EUR$4,799USD£3,753GBP
- Report
- October 2025
- 456 Pages
Global
From €4518EUR$4,950USD£3,871GBP
- Report
- June 2026
- 200 Pages
Global
From €2729EUR$2,990USD£2,339GBP
- Report
- April 2026
- 200 Pages
Global
From €2729EUR$2,990USD£2,339GBP
- Report
- May 2026
- 150 Pages
Global
From €5431EUR$5,950USD£4,654GBP
- Report
- September 2026
- 195 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- September 2026
- 191 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- September 2026
- 186 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- January 2026
- 184 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- January 2026
- 185 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- September 2026
- 179 Pages
Global
From €5339EUR$5,850USD£4,575GBP
- Report
- September 2026
- 471 Pages
Global
From €5339EUR$5,850USD£4,575GBP
- Report
- September 2026
- 197 Pages
Global
From €5339EUR$5,850USD£4,575GBP
- Report
- September 2026
- 288 Pages
Global
From €5339EUR$5,850USD£4,575GBP

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more